Event-free survival rates in infant ALL.
Trial . | Event-Free Survival . | Reference . |
---|---|---|
CCG 107 | 33% EFS @ 4 yrs | Reaman2 |
CCG 1883 | 39% EFS @ 4 yrs | |
3% t(4;11)* | ||
50% other 11q23* | ||
49% normal karyotype* | Reaman8 | |
POG 8493 | 28% EFS @ 4 yrs | |
57% > 9 mos old @ diagnosis | ||
18% < 9 mos old @ diagnosis | Frankel3 | |
BFM 83, 86, 90 | 43% pEFS @ 6 yrs | |
53% Prednisone good response | ||
15% Prednisone poor response | Dordelmann7 | |
CLCG-EORTC 58881 | 41% EFS @ 4 yrs | Ferster5 |
UK ALL VIII, X, pilot | 24% @ 6 yrs | |
40% > 6 mos old @ diagnosis | ||
10% < 6 mos old @ diagnosis | Chessells4 | |
Total Therapy X-XIII | EFS @ 5 yrs | |
56% (-)11q23/MLL rearrangements | ||
6% (+)11q23/MLL rearrangements | ||
42% > 6 mos old @ diagnosis | ||
8% < 6 mos old @ diagnosis | Pui6 | |
Dana Farber Consortium | 54% DFS @ 50 mos | Silverman44 |
Trial . | Event-Free Survival . | Reference . |
---|---|---|
CCG 107 | 33% EFS @ 4 yrs | Reaman2 |
CCG 1883 | 39% EFS @ 4 yrs | |
3% t(4;11)* | ||
50% other 11q23* | ||
49% normal karyotype* | Reaman8 | |
POG 8493 | 28% EFS @ 4 yrs | |
57% > 9 mos old @ diagnosis | ||
18% < 9 mos old @ diagnosis | Frankel3 | |
BFM 83, 86, 90 | 43% pEFS @ 6 yrs | |
53% Prednisone good response | ||
15% Prednisone poor response | Dordelmann7 | |
CLCG-EORTC 58881 | 41% EFS @ 4 yrs | Ferster5 |
UK ALL VIII, X, pilot | 24% @ 6 yrs | |
40% > 6 mos old @ diagnosis | ||
10% < 6 mos old @ diagnosis | Chessells4 | |
Total Therapy X-XIII | EFS @ 5 yrs | |
56% (-)11q23/MLL rearrangements | ||
6% (+)11q23/MLL rearrangements | ||
42% > 6 mos old @ diagnosis | ||
8% < 6 mos old @ diagnosis | Pui6 | |
Dana Farber Consortium | 54% DFS @ 50 mos | Silverman44 |
includes CCG 107; Abbreviations: EFS, event-free survival; DFS, disease-free survival; CCG Children's Cancer Group; POG, Pediatric Oncology Group; BFM, Berlin-Frankfurt-Münster; CLCG-EORTC, Children's Leukemia Cooperative Group of the European Oncology Research and Treatment Cooperative